Likewise, targeted treatment against EPHA2 could be of value in combination with tamoxifen or trastuzumab in mutually EPHA2- and ER- or EPHA2- and HER2-positive subgroups of invasive breast cancer patients, respectively [17,26,44,69]. Here, ERBB2 is linked to invasive breast carcinoma.